Technical Analysis for IMNM - Immunome, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -2.30% | |
| Fell Below 20 DMA | Bearish | -1.77% | |
| Gapped Down | Weakness | -1.77% | |
| Shooting Star Candlestick | Bearish | -7.37% | |
| Lizard Bearish | Bearish Day Trade Setup | -7.37% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.37% | |
| Crossed Above 20 DMA | Bullish | -7.37% | |
| Pocket Pivot | Bullish Swing Setup | -7.37% | |
| Doji - Bearish? | Reversal | -7.37% | |
| Wide Bands | Range Expansion | -7.37% |
| Alert | Time |
|---|---|
| Down 3% | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 1% | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 23 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/12/2024
Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Clinical Medicine Immunology Immune System Antibodies Tumor Cancer Immunotherapy Monoclonal Antibodies Monoclonal Antibody Antibody Glycoproteins Antigen Symphogen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Clinical Medicine Immunology Immune System Antibodies Tumor Cancer Immunotherapy Monoclonal Antibodies Monoclonal Antibody Antibody Glycoproteins Antigen Symphogen
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
T
TraderMike 3 months ago
I was in the right place at the right time on this today. 🎉 I actually bought it yesterday after it made a (you guessed it)Â
Non-ADX 1,2,3,4 Bullish signal the day before. I sold half around 21 and am still holding the other half of the shares. Â
Non-ADX 1,2,3,4 Bullish signal the day before. I sold half around 21 and am still holding the other half of the shares. Â
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 30.958 |
| 52 Week Low | 4.5 |
| Average Volume | 726,347 |
| 200-Day Moving Average | 13.16 |
| 50-Day Moving Average | 19.58 |
| 20-Day Moving Average | 15.04 |
| 10-Day Moving Average | 15.33 |
| Average True Range | 1.09 |
| RSI (14) | 35.48 |
| ADX | 21.36 |
| +DI | 20.36 |
| -DI | 26.78 |
| Chandelier Exit (Long, 3 ATRs) | 15.80 |
| Chandelier Exit (Short, 3 ATRs) | 16.97 |
| Upper Bollinger Bands | 16.62 |
| Lower Bollinger Band | 13.45 |
| Percent B (%b) | 0.43 |
| BandWidth | 21.08 |
| MACD Line | -1.12 |
| MACD Signal Line | -1.39 |
| MACD Histogram | 0.2773 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.41 | ||||
| Resistance 3 (R3) | 16.54 | 16.13 | 16.14 | ||
| Resistance 2 (R2) | 16.13 | 15.72 | 16.07 | 16.05 | |
| Resistance 1 (R1) | 15.47 | 15.47 | 15.27 | 15.34 | 15.96 |
| Pivot Point | 15.06 | 15.06 | 14.96 | 15.00 | 15.06 |
| Support 1 (S1) | 14.40 | 14.65 | 14.20 | 14.27 | 13.64 |
| Support 2 (S2) | 13.99 | 14.40 | 13.93 | 13.55 | |
| Support 3 (S3) | 13.33 | 13.99 | 13.46 | ||
| Support 4 (S4) | 13.20 |
